fda safety communication semaglutide naion 2025 and the Risk of Nonarteritic Ischemic Optic Neuropathy fda drug safety communication naion

This affects roughly 1 in 3 people and is particularly common in the first few months

The background risk for miscarriage occurs at a rate of 18%

Sign up below, then look for a confirmation email in your inbox.

These findings open a new frontier in personalized neuroendocrine therapy, particularly relevant for postmenopausal women, who bear a disproportionate burden of AD and are often underrepresented in clinical trials

Metformin remains the first-line treatment for most people with newly diagnosed type 2 diabetes because it is safe, effective, and inexpensive

Clinical Applications As shown in Table 2, depletion of GSH has been implicated in many chronic degenerative diseases